Literature DB >> 6971938

Immunobiology of D-penicillamine.

R L Dawkins, P J Zilko, J Carrano, M J Garlepp, B L McDonald.   

Abstract

D-penicillamine holds the key to a better understanding of autoimmunization and the pathogenesis of autoimmune disease. Analysis of its mode of action is complicated by its multiplicity of effects. In respect to anti-acetylcholine receptors and myasthenia gravis, the major effect may be at the level of immunoregulation and/or immunogenicity. Anti-striated muscle antibody is much more common and is influenced by the HLA antigen of the patient. Thus, HLA-linked immune response genes may be involved.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971938

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  5 in total

1.  Rapid progression of scleroderma possibly associated with penicillamine therapy.

Authors:  Y S Haviv; R Safadi
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

2.  Studies of the effect of D-penicillamine and sodium aurothiomalate therapy on superoxide anion production by monocytes from patients with rheumatoid arthritis: evidence for in vivo stimulation of monocytes.

Authors:  N P Hurst; A L Bell; G Nuki
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

3.  Polymyositis complicating D-penicillamine treatment.

Authors:  A O Aydintug; R Cervera; D D'Cruz; G Ramírez; R A Asherson; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

4.  Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus.

Authors:  A A Borg; M J Davis; P T Dawes; M F Shadforth
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

5.  Human nicotinic acetylcholine receptor alpha-subunit isoforms: origins and expression.

Authors:  C MacLennan; D Beeson; A Vincent; J Newsom-Davis
Journal:  Nucleic Acids Res       Date:  1993-11-25       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.